Publicaciones en colaboración con investigadores/as de Complexo Hospitalario Universitario da Coruña (20)

2024

  1. SLESIS-R: an improved score for prediction of serious infection in patients with systemic lupus erythematosus based on the RELESSER prospective cohort

    Lupus Science and Medicine, Vol. 11, Núm. 1

2023

  1. Central nervous system involvement in systemic lupus erythematosus: Data from the Spanish Society of Rheumatology Lupus Register (RELESSER)

    Seminars in Arthritis and Rheumatism, Vol. 58

  2. Confounders contributing to explain the association between sex and disease impact in patients with recent-onset psoriatic arthritis

    Clinical and experimental rheumatology, Vol. 41, Núm. 1, pp. 137-144

  3. Moderate-High Disease Activity in Patients with Recent-Onset Psoriatic Arthritis—Multivariable Prediction Model Based on Machine Learning

    Journal of Clinical Medicine, Vol. 12, Núm. 3

2022

  1. Antimalarials exert a cardioprotective effect in lupus patients: Insights from the Spanish Society of Rheumatology Lupus Register (RELESSER) analysis of factors associated with heart failure

    Seminars in Arthritis and Rheumatism, Vol. 52

  2. Characteristics associated with the perception of high-impact disease (PsAID ≥4) in patients with recent-onset psoriatic arthritis. Machine learning-based model

    Seminars in Arthritis and Rheumatism, Vol. 57

  3. Minimal disease activity (MDA) in patients with recent-onset psoriatic arthritis: predictive model based on machine learning

    Arthritis research & therapy, Vol. 24, Núm. 1, pp. 153

  4. Severe Disease in Patients With Recent-Onset Psoriatic Arthritis. Prediction Model Based on Machine Learning

    Frontiers in Medicine, Vol. 9

2021

  1. Food groups associated with immune-mediated inflammatory diseases: a Mendelian randomization and disease severity study

    European Journal of Clinical Nutrition, Vol. 75, Núm. 9, pp. 1368-1382

  2. Relevance of gastrointestinal manifestations in a large Spanish cohort of patients with systemic lupus erythematosus: what do we know?

    Rheumatology (Oxford, England), Vol. 60, Núm. 11, pp. 5329-5336

2020

  1. Differences in clinical manifestations and increased severity of systemic lupus erythematosus between two groups of Hispanics: European Caucasians versus Latin American mestizos (data from the RELESSER registry)

    Lupus, Vol. 29, Núm. 1, pp. 27-36

  2. Hydroxychloroquine is associated with a lower risk of polyautoimmunity: Data from the RELESSER Registry

    Rheumatology (United Kingdom), Vol. 59, Núm. 8, pp. 2043-2051

2019

  1. Genetic variation at the glycosaminoglycan metabolism pathway contributes to the risk of psoriatic arthritis but not psoriasis

    Annals of the Rheumatic Diseases, Vol. 78, Núm. 3, pp. 355-364

2017

  1. Diagnostic Value and Validity of Early Spondyloarthritis Features: Results From a National Spanish Cohort

    Arthritis Care and Research, Vol. 69, Núm. 6, pp. 938-942

2016

  1. Characterization of patients with lupus nephritis included in a large cohort from the Spanish society of rheumatology registry of patients with systemic lupus erythematosus (RELESSER)

    Medicine (United States), Vol. 95, Núm. 9

  2. Relationship between damage clustering and mortality in systemic lupus erythematosus in early and late stages of the disease: Cluster analyses in a large cohort from the Spanish Society of Rheumatology Lupus Registry

    Rheumatology (United Kingdom), Vol. 55, Núm. 7, pp. 1243-1250

  3. Urine metabolome profiling of immune-mediated inflammatory diseases

    BMC Medicine, Vol. 14, Núm. 1

2015

  1. Comprehensive description of clinical characteristics of a large systemic lupus erythematosus cohort from the spanish rheumatology society lupus registry (RELESSER) with emphasis on complete versus incomplete lupus differences

    Medicine (United States), Vol. 94, Núm. 1, pp. e267

2012

  1. Clinical features of late-onset ankylosing spondylitis: Comparison with early-onset disease

    Journal of Rheumatology, Vol. 39, Núm. 5, pp. 1008-1012

  2. FCGR2A/CD32A and FCGR3A/CD16A variants and EULAR response to tumor necrosis factor-α blockers in psoriatic arthritis: A longitudinal study with 6 months of followup

    Journal of Rheumatology, Vol. 39, Núm. 5, pp. 1035-1041